26
|
Peraldo-Neia C, Ostano P, Cavalloni G, Pignochino Y, Sangiolo D, De Cecco L, Marchesi E, Ribero D, Scarpa A, De Rose AM, Giuliani A, Calise F, Raggi C, Invernizzi P, Aglietta M, Chiorino G, Leone F. Transcriptomic analysis and mutational status of IDH1 in paired primary-recurrent intrahepatic cholangiocarcinoma. BMC Genomics 2018; 19:440. [PMID: 29871612 PMCID: PMC5989353 DOI: 10.1186/s12864-018-4829-0] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2017] [Accepted: 05/25/2018] [Indexed: 12/14/2022] Open
Abstract
Background Effective target therapies for intrahepatic cholangiocarcinoma (ICC) have not been identified so far. One of the reasons may be the genetic evolution from primary (PR) to recurrent (REC) tumors. We aim to identify peculiar characteristics and to select potential targets specific for recurrent tumors. Eighteen ICC paired PR and REC tumors were collected from 5 Italian Centers. Eleven pairs were analyzed for gene expression profiling and 16 for mutational status of IDH1. For one pair, deep mutational analysis by Next Generation Sequencing was also carried out. An independent cohort of patients was used for validation. Results Two class-paired comparison yielded 315 differentially expressed genes between REC and PR tumors. Up-regulated genes in RECs are involved in RNA/DNA processing, cell cycle, epithelial to mesenchymal transition (EMT), resistance to apoptosis, and cytoskeleton remodeling. Down-regulated genes participate to epithelial cell differentiation, proteolysis, apoptotic, immune response, and inflammatory processes. A 24 gene signature is able to discriminate RECs from PRs in an independent cohort; FANCG is statistically associated with survival in the chol-TCGA dataset. IDH1 was mutated in the RECs of five patients; 4 of them displayed the mutation only in RECs. Deep sequencing performed in one patient confirmed the IDH1 mutation in REC. Conclusions RECs are enriched for genes involved in EMT, resistance to apoptosis, and cytoskeleton remodeling. Key players of these pathways might be considered druggable targets in RECs. IDH1 is mutated in 30% of RECs, becoming both a marker of progression and a target for therapy. Electronic supplementary material The online version of this article (10.1186/s12864-018-4829-0) contains supplementary material, which is available to authorized users.
Collapse
|
27
|
Fenocchio E, Colombi F, Calella M, Filippi R, Depetris I, Lombardi P, Marino D, Cagnazzo C, Ferraris R, Vaira M, Aglietta M, Leone F. Improvement of metastatic colorectal cancer patient survival: Single institution experience. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy151.256] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
28
|
Leuci V, Casucci GM, Grignani G, Rotolo R, Rossotti U, Vigna E, Gammaitoni L, Mesiano G, Fiorino E, Donini C, Pisacane A, Ambrosio LD, Pignochino Y, Aglietta M, Bondanza A, Sangiolo D. CD44v6 as innovative sarcoma target for CAR-redirected CIK cells. Oncoimmunology 2018; 7:e1423167. [PMID: 29721373 PMCID: PMC5927525 DOI: 10.1080/2162402x.2017.1423167] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2017] [Revised: 12/22/2017] [Accepted: 12/22/2017] [Indexed: 12/22/2022] Open
Abstract
Purpose of our study was to explore a new immunotherapy for high grade soft tissue sarcomas (STS) based on cytokine-induced killer cells (CIK) redirected with a chimeric antigen receptor (CAR) against the tumor-promoting antigen CD44v6. We aimed at generating bipotential killers, combining the CAR specificity with the intrinsic tumor-killing ability of CIK cells (CAR+.CIK). We set a patient-derived experimental platform. CAR+.CIK were generated by transduction of CIK precursors with a lentiviral vector encoding for anti-CD44v6-CAR. CAR+.CIK were characterized and assessed in vitro against multiple histotypes of patient-derived STS. The anti-sarcoma activity of CAR+.CIK was confirmed in a STS xenograft model. CD44v6 was expressed by 40% (11/27) of patient-derived STS. CAR+.CIK were efficiently expanded from patients (n = 12) and killed multiple histotypes of STS (including autologous targets, n = 4). The killing activity was significantly higher compared with unmodified CIK, especially at low effector/target (E/T) ratios: 98% vs 82% (E/T = 10:1) and 68% vs 26% (1:4), (p<0.0001). Specificity of tumor killing was confirmed by blocking with anti-CD44v6 antibody. CAR+.CIK produced higher amounts of IL6 and IFN-γ compared to control CIK. CAR+.CIK were highly active in mice bearing subcutaneous STS xenografts, with significant delay of tumor growth (p<0.0001) without toxicities. We report first evidence of CAR+.CIK's activity against high grade STS and propose CD44v6 as an innovative target in this setting. CIK are a valuable platform for the translation of CAR-based strategies to challenging field of solid tumors. Our findings support the exploration of CAR+.CIK in clinical trials against high grade STS.
Collapse
|
29
|
Aab A, Abreu P, Aglietta M, Al Samarai I, Albuquerque I, Allekotte I, Almela A, Alvarez Castillo J, Alvarez-Muñiz J, Anastasi G, Anchordoqui L, Andrada B, Andringa S, Aramo C, Arqueros F, Arsene N, Asorey H, Assis P, Aublin J, Avila G, Badescu A, Balaceanu A, Barbato F, Barreira Luz R, Beatty J, Becker K, Bellido J, Berat C, Bertaina M, Bertou X, Biermann P, Biteau J, Blaess S, Blanco A, Blazek J, Bleve C, Boháčová M, Boncioli D, Bonifazi C, Borodai N, Botti A, Brack J, Brancus I, Bretz T, Bridgeman A, Briechle F, Buchholz P, Bueno A, Buitink S, Buscemi M, Caballero-Mora K, Caccianiga L, Cancio A, Canfora F, Caramete L, Caruso R, Castellina A, Catalani F, Cataldi G, Cazon L, Chavez A, Chinellato J, Chudoba J, Clay R, Cobos A, Colalillo R, Coleman A, Collica L, Coluccia M, Conceição R, Consolati G, Contreras F, Cooper M, Coutu S, Covault C, Cronin J, D’Amico S, Daniel B, Dasso S, Daumiller K, Dawson B, de Almeida R, de Jong S, De Mauro G, de Mello Neto J, De Mitri I, de Oliveira J, de Souza V, Debatin J, Deligny O, Díaz Castro M, Diogo F, Dobrigkeit C, D’Olivo J, Dorosti Q, dos Anjos R, Dova M, Dundovic A, Ebr J, Engel R, Erdmann M, Erfani M, Escobar C, Espadanal J, Etchegoyen A, Falcke H, Farmer J, Farrar G, Fauth A, Fazzini N, Fenu F, Fick B, Figueira J, Filipčič A, Fratu O, Freire M, Fujii T, Fuster A, Gaior R, García B, Garcia-Pinto D, Gaté F, Gemmeke H, Gherghel-Lascu A, Ghia P, Giaccari U, Giammarchi M, Giller M, Głas D, Glaser C, Golup G, Gómez Berisso M, Gómez Vitale P, González N, Gorgi A, Gorham P, Grillo A, Grubb T, Guarino F, Guedes G, Halliday R, Hampel M, Hansen P, Harari D, Harrison T, Harton J, Haungs A, Hebbeker T, Heck D, Heimann P, Herve A, Hill G, Hojvat C, Holt E, Homola P, Hörandel J, Horvath P, Hrabovský M, Huege T, Hulsman J, Insolia A, Isar P, Jandt I, Johnsen J, Josebachuili M, Jurysek J, Kääpä A, Kambeitz O, Kampert K, Keilhauer B, Kemmerich N, Kemp E, Kemp J, Kieckhafer R, Klages H, Kleifges M, Kleinfeller J, Krause R, Krohm N, Kuempel D, Kukec Mezek G, Kunka N, Kuotb Awad A, Lago B, LaHurd D, Lang R, Lauscher M, Legumina R, Leigui de Oliveira M, Letessier-Selvon A, Lhenry-Yvon I, Link K, Lo Presti D, Lopes L, López R, López Casado A, Lorek R, Luce Q, Lucero A, Malacari M, Mallamaci M, Mandat D, Mantsch P, Mariazzi A, Mariş I, Marsella G, Martello D, Martinez H, Martínez Bravo O, Masías Meza J, Mathes H, Mathys S, Matthews J, Matthews J, Matthiae G, Mayotte E, Mazur P, Medina C, Medina-Tanco G, Melo D, Menshikov A, Merenda KD, Michal S, Micheletti M, Middendorf L, Miramonti L, Mitrica B, Mockler D, Mollerach S, Montanet F, Morello C, Mostafá M, Müller A, Müller G, Muller M, Müller S, Mussa R, Naranjo I, Nellen L, Nguyen P, Niculescu-Oglinzanu M, Niechciol M, Niemietz L, Niggemann T, Nitz D, Nosek D, Novotny V, Nožka L, Núñez L, Ochilo L, Oikonomou F, Olinto A, Palatka M, Pallotta J, Papenbreer P, Parente G, Parra A, Paul T, Pech M, Pedreira F, Pękala J, Pelayo R, Peña-Rodriguez J, Pereira L, Perlin M, Perrone L, Peters C, Petrera S, Phuntsok J, Piegaia R, Pierog T, Pimenta M, Pirronello V, Platino M, Plum M, Porowski C, Prado R, Privitera P, Prouza M, Quel E, Querchfeld S, Quinn S, Ramos-Pollan R, Rautenberg J, Ravignani D, Ridky J, Riehn F, Risse M, Ristori P, Rizi V, Rodrigues de Carvalho W, Rodriguez Fernandez G, Rodriguez Rojo J, Rogozin D, Roncoroni M, Roth M, Roulet E, Rovero A, Ruehl P, Saffi S, Saftoiu A, Salamida F, Salazar H, Saleh A, Salesa Greus F, Salina G, Sánchez F, Sanchez-Lucas P, Santos E, Santos E, Sarazin F, Sarmento R, Sarmiento-Cano C, Sato R, Schauer M, Scherini V, Schieler H, Schimp M, Schmidt D, Scholten O, Schovánek P, Schröder F, Schröder S, Schulz A, Schumacher J, Sciutto S, Segreto A, Shadkam A, Shellard R, Sigl G, Silli G, Sima O, Śmiałkowski A, Šmída R, Smith B, Snow G, Sommers P, Sonntag S, Squartini R, Stanca D, Stanič S, Stasielak J, Stassi P, Stolpovskiy M, Strafella F, Streich A, Suarez F, Suarez Durán M, Sudholz T, Suomijärvi T, Supanitsky A, Šupík J, Swain J, Szadkowski Z, Taboada A, Taborda O, Theodoro V, Timmermans C, Todero Peixoto C, Tomankova L, Tomé B, Torralba Elipe G, Travnicek P, Trini M, Ulrich R, Unger M, Urban M, Valdés Galicia J, Valiño I, Valore L, van Aar G, van Bodegom P, van den Berg A, van Vliet A, Varela E, Vargas Cárdenas B, Varner G, Vázquez R, Veberič D, Ventura C, Vergara Quispe I, Verzi V, Vicha J, Villaseñor L, Vorobiov S, Wahlberg H, Wainberg O, Walz D, Watson A, Weber M, Weindl A, Wiencke L, Wilczyński H, Wileman C, Wirtz M, Wittkowski D, Wundheiler B, Yang L, Yushkov A, Zas E, Zavrtanik D, Zavrtanik M, Zepeda A, Zimmermann B, Ziolkowski M, Zong Z, Zuccarello F. Inferences on mass composition and tests of hadronic interactions from 0.3 to 100 EeV using the water-Cherenkov detectors of the Pierre Auger Observatory. Int J Clin Exp Med 2017. [DOI: 10.1103/physrevd.96.122003] [Citation(s) in RCA: 63] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
30
|
Fenocchio E, Colombi F, Calella M, Filippi R, Depetris I, Chilà G, Lombardi P, Marino D, Cagnazzo C, Ferraris R, Aglietta M, Leone F. Survival of metastatic colorectal cancer patients at Candiolo Cancer Institute. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx422.027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
31
|
Leone F, Filippi R, Palloni A, Fornaro L, Casadei Gardini A, Aprile G, Silvestris N, Satolli M, Faloppi L, Daniele S, Lutrino E, Vivaldi C, Frassineti G, Garattini S, Brunetti O, Russano M, Scartozzi M, Cagnazzo C, Aglietta M, Giovanni B. Prognostic factors in unresectable biliary tract cancer: a GICO (Gruppo Italiano COlangiocarcinoma) retrospective analysis. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx425.013] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
32
|
André T, Overman M, Lonardi S, Aglietta M, McDermott R, Wong K, Morse M, Hendlisz A, Moss R, Ledeine JM, Tang H, Cao Z, Kopetz S. Analysis of tumor PD-L1 expression and biomarkers in relation to clinical activity in patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC) treated with nivolumab (NIVO) + ipilimumab (IPI): CheckMate 142. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx393.011] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
33
|
Aab A, Abreu P, Aglietta M, Ahn EJ, Al Samarai I, Albuquerque IFM, Allekotte I, Allen JD, Allison P, Almela A, Alvarez Castillo J, Alvarez-Muñiz J, Ambrosio M, Anastasi GA, Anchordoqui L, Andrada B, Andringa S, Aramo C, Arqueros F, Arsene N, Asorey H, Assis P, Aublin J, Avila G, Badescu AM, Baus C, Beatty JJ, Becker KH, Bellido JA, Berat C, Bertaina ME, Bertou X, Biermann PL, Billoir P, Biteau J, Blaess SG, Blanco A, Blazek J, Bleve C, Blümer H, Boháčová M, Boncioli D, Bonifazi C, Borodai N, Botti AM, Brack J, Brancus I, Bretz T, Bridgeman A, Briechle FL, Buchholz P, Bueno A, Buitink S, Buscemi M, Caballero-Mora KS, Caccianiga B, Caccianiga L, Cancio A, Canfora F, Caramete L, Caruso R, Castellina A, Cataldi G, Cazon L, Cester R, Chavez AG, Chiavassa A, Chinellato JA, Chirinos Diaz JC, Chudoba J, Clay RW, Colalillo R, Coleman A, Collica L, Coluccia MR, Conceição R, Contreras F, Cooper MJ, Coutu S, Covault CE, Cronin J, Dallier R, D'Amico S, Daniel B, Dasso S, Daumiller K, Dawson BR, de Almeida RM, de Jong SJ, De Mauro G, de Mello Neto JRT, De Mitri I, de Oliveira J, de Souza V, Debatin J, Del Peral L, Deligny O, Dhital N, Di Giulio C, Di Matteo A, Díaz Castro ML, Diogo F, Dobrigkeit C, D'Olivo JC, Dorofeev A, Dos Anjos RC, Dova MT, Dundovic A, Ebr J, Engel R, Erdmann M, Erfani M, Escobar CO, Espadanal J, Etchegoyen A, Falcke H, Fang K, Farrar GR, Fauth AC, Fazzini N, Ferguson AP, Fick B, Figueira JM, Filevich A, Filipčič A, Fratu O, Freire MM, Fujii T, Fuster A, Gallo F, García B, Garcia-Pinto D, Gate F, Gemmeke H, Gherghel-Lascu A, Ghia PL, Giaccari U, Giammarchi M, Giller M, Głas D, Glaser C, Glass H, Golup G, Gómez Berisso M, Gómez Vitale PF, González N, Gookin B, Gordon J, Gorgi A, Gorham P, Gouffon P, Griffith N, Grillo AF, Grubb TD, Guarino F, Guedes GP, Hampel MR, Hansen P, Harari D, Harrison TA, Harton JL, Hasankiadeh Q, Haungs A, Hebbeker T, Heck D, Heimann P, Herve AE, Hill GC, Hojvat C, Hollon N, Holt E, Homola P, Hörandel JR, Horvath P, Hrabovský M, Huege T, Hulsman J, Insolia A, Isar PG, Jandt I, Jansen S, Jarne C, Johnsen JA, Josebachuili M, Kääpä A, Kambeitz O, Kampert KH, Kasper P, Katkov I, Keilhauer B, Kemp E, Kieckhafer RM, Klages HO, Kleifges M, Kleinfeller J, Krause R, Krohm N, Kuempel D, Kukec Mezek G, Kunka N, Kuotb Awad A, LaHurd D, Latronico L, Lauscher M, Lautridou P, Lebrun P, Legumina R, Leigui de Oliveira MA, Letessier-Selvon A, Lhenry-Yvon I, Link K, Lopes L, López R, López Casado A, Lucero A, Malacari M, Mallamaci M, Mandat D, Mantsch P, Mariazzi AG, Marin V, Mariş IC, Marsella G, Martello D, Martinez H, Martínez Bravo O, Masías Meza JJ, Mathes HJ, Mathys S, Matthews J, Matthews JAJ, Matthiae G, Maurizio D, Mayotte E, Mazur PO, Medina C, Medina-Tanco G, Mello VBB, Melo D, Menshikov A, Messina S, Micheletti MI, Middendorf L, Minaya IA, Miramonti L, Mitrica B, Molina-Bueno L, Mollerach S, Montanet F, Morello C, Mostafá M, Moura CA, Müller G, Muller MA, Müller S, Naranjo I, Navas S, Necesal P, Nellen L, Nelles A, Neuser J, Nguyen PH, Niculescu-Oglinzanu M, Niechciol M, Niemietz L, Niggemann T, Nitz D, Nosek D, Novotny V, Nožka H, Núñez LA, Ochilo L, Oikonomou F, Olinto A, Pakk Selmi-Dei D, Palatka M, Pallotta J, Papenbreer P, Parente G, Parra A, Paul T, Pech M, Pedreira F, Pękala J, Pelayo R, Peña-Rodriguez J, Pepe IM, Pereira LAS, Perrone L, Petermann E, Peters C, Petrera S, Phuntsok J, Piegaia R, Pierog T, Pieroni P, Pimenta M, Pirronello V, Platino M, Plum M, Porowski C, Prado RR, Privitera P, Prouza M, Quel EJ, Querchfeld S, Quinn S, Rautenberg J, Ravel O, Ravignani D, Revenu B, Ridky J, Risse M, Ristori P, Rizi V, Rodrigues de Carvalho W, Rodriguez Rojo J, Rodríguez-Frías MD, Rogozin D, Rosado J, Roth M, Roulet E, Rovero AC, Saffi SJ, Saftoiu A, Salazar H, Saleh A, Salesa Greus F, Salina G, Sanabria Gomez JD, Sánchez F, Sanchez-Lucas P, Santos EM, Santos E, Sarazin F, Sarkar B, Sarmento R, Sarmiento-Cano C, Sato R, Scarso C, Schauer M, Scherini V, Schieler H, Schmidt D, Scholten O, Schoorlemmer H, Schovánek P, Schröder FG, Schulz A, Schulz J, Schumacher J, Sciutto SJ, Segreto A, Settimo M, Shadkam A, Shellard RC, Sigl G, Sima O, Śmiałkowski A, Šmída R, Snow GR, Sommers P, Sonntag S, Sorokin J, Squartini R, Stanca D, Stanič S, Stapleton J, Stasielak J, Strafella F, Stutz A, Suarez F, Suarez Durán M, Sudholz T, Suomijärvi T, Supanitsky AD, Sutherland MS, Swain J, Szadkowski Z, Taborda OA, Tapia A, Tepe A, Theodoro VM, Timmermans C, Todero Peixoto CJ, Tomankova L, Tomé B, Tonachini A, Torralba Elipe G, Torres Machado D, Travnicek P, Trini M, Ulrich R, Unger M, Urban M, Valbuena-Delgado A, Valdés Galicia JF, Valiño I, Valore L, van Aar G, van Bodegom P, van den Berg AM, van Vliet A, Varela E, Vargas Cárdenas B, Varner G, Vázquez JR, Vázquez RA, Veberič D, Verzi V, Vicha J, Videla M, Villaseñor L, Vorobiov S, Wahlberg H, Wainberg O, Walz D, Watson AA, Weber M, Weindl A, Wiencke L, Wilczyński H, Winchen T, Wittkowski D, Wundheiler B, Wykes S, Yang L, Yapici T, Yelos D, Zas E, Zavrtanik D, Zavrtanik M, Zepeda A, Zimmermann B, Ziolkowski M, Zong Z, Zuccarello F. Testing Hadronic Interactions at Ultrahigh Energies with Air Showers Measured by the Pierre Auger Observatory. PHYSICAL REVIEW LETTERS 2016; 117:192001. [PMID: 27858429 DOI: 10.1103/physrevlett.117.192001] [Citation(s) in RCA: 35] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/23/2016] [Indexed: 06/06/2023]
Abstract
Ultrahigh energy cosmic ray air showers probe particle physics at energies beyond the reach of accelerators. Here we introduce a new method to test hadronic interaction models without relying on the absolute energy calibration, and apply it to events with primary energy 6-16 EeV (E_{CM}=110-170 TeV), whose longitudinal development and lateral distribution were simultaneously measured by the Pierre Auger Observatory. The average hadronic shower is 1.33±0.16 (1.61±0.21) times larger than predicted using the leading LHC-tuned models EPOS-LHC (QGSJetII-04), with a corresponding excess of muons.
Collapse
|
34
|
Sartore-Bianchi A, Marsoni S, Trusolino L, Martino C, Lonardi S, Leone F, Cottino F, Vurchio V, Valtorta E, Lauricella C, Zagonel V, Racca P, Ciardiello F, Ardizzoni A, Tonini G, Aglietta M, Siena S. Pertuzumab and trastuzumab-emtansine in HER2 positive metastatic colorectal cancer: the HERACLES B TRIAL. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw335.26] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
35
|
Marsoni S, Siena S, Martino C, Depetris I, Sartore-Bianchi A, Di Fabio F, Ponzetti A, Fioroni I, Lonardi S, Cassoni P, Truini M, Fiorentino M, Crescenzi A, Rugge M, Leone F, Racca P, Zagonel V, Ciardiello F, Sapino A, Aglietta M. The FUNNEL: a precision medicine project for metastatic colorectal cancer. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw335.28] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
36
|
Aab A, Abreu P, Aglietta M, Ahn EJ, Al Samarai I, Albuquerque IFM, Allekotte I, Allison P, Almela A, Alvarez Castillo J, Alvarez-Muñiz J, Alves Batista R, Ambrosio M, Aminaei A, Anastasi GA, Anchordoqui L, Andringa S, Aramo C, Arqueros F, Arsene N, Asorey H, Assis P, Aublin J, Avila G, Awal N, Badescu AM, Baus C, Beatty JJ, Becker KH, Bellido JA, Berat C, Bertaina ME, Bertou X, Biermann PL, Billoir P, Blaess SG, Blanco A, Blanco M, Blazek J, Bleve C, Blümer H, Boháčová M, Boncioli D, Bonifazi C, Borodai N, Brack J, Brancus I, Bretz T, Bridgeman A, Brogueira P, Buchholz P, Bueno A, Buitink S, Buscemi M, Caballero-Mora KS, Caccianiga B, Caccianiga L, Candusso M, Caramete L, Caruso R, Castellina A, Cataldi G, Cazon L, Cester R, Chavez AG, Chiavassa A, Chinellato JA, Chudoba J, Cilmo M, Clay RW, Cocciolo G, Colalillo R, Coleman A, Collica L, Coluccia MR, Conceição R, Contreras F, Cooper MJ, Cordier A, Coutu S, Covault CE, Cronin J, Dallier R, Daniel B, Dasso S, Daumiller K, Dawson BR, de Almeida RM, de Jong SJ, De Mauro G, de Mello Neto JRT, De Mitri I, de Oliveira J, de Souza V, Del Peral L, Deligny O, Dhital N, Di Giulio C, Di Matteo A, Diaz JC, Díaz Castro ML, Diogo F, Dobrigkeit C, Docters W, D'Olivo JC, Dorofeev A, Dorosti Hasankiadeh Q, Dos Anjos RC, Dova MT, Ebr J, Engel R, Erdmann M, Erfani M, Escobar CO, Espadanal J, Etchegoyen A, Falcke H, Fang K, Farrar G, Fauth AC, Fazzini N, Ferguson AP, Fick B, Figueira JM, Filevich A, Filipčič A, Fratu O, Freire MM, Fujii T, García B, Garcia-Gamez D, Garcia-Pinto D, Gate F, Gemmeke H, Gherghel-Lascu A, Ghia PL, Giaccari U, Giammarchi M, Giller M, Głas D, Glaser C, Glass H, Golup G, Gómez Berisso M, Gómez Vitale PF, González N, Gookin B, Gordon J, Gorgi A, Gorham P, Gouffon P, Griffith N, Grillo AF, Grubb TD, Guarino F, Guedes GP, Hampel MR, Hansen P, Harari D, Harrison TA, Hartmann S, Harton JL, Haungs A, Hebbeker T, Heck D, Heimann P, Herve AE, Hill GC, Hojvat C, Hollon N, Holt E, Homola P, Hörandel JR, Horvath P, Hrabovský M, Huber D, Huege T, Insolia A, Isar PG, Jandt I, Jansen S, Jarne C, Johnsen JA, Josebachuili M, Kääpä A, Kambeitz O, Kampert KH, Kasper P, Katkov I, Keilhauer B, Kemp E, Kieckhafer RM, Klages HO, Kleifges M, Kleinfeller J, Krause R, Krohm N, Kuempel D, Kukec Mezek G, Kunka N, Kuotb Awad AW, LaHurd D, Latronico L, Lauer R, Lauscher M, Lautridou P, Le Coz S, Lebrun D, Lebrun P, Leigui de Oliveira MA, Letessier-Selvon A, Lhenry-Yvon I, Link K, Lopes L, López R, López Casado A, Louedec K, Lucero A, Malacari M, Mallamaci M, Maller J, Mandat D, Mantsch P, Mariazzi AG, Marin V, Mariş IC, Marsella G, Martello D, Martinez H, Martínez Bravo O, Martraire D, Masías Meza JJ, Mathes HJ, Mathys S, Matthews J, Matthews JAJ, Matthiae G, Maurizio D, Mayotte E, Mazur PO, Medina C, Medina-Tanco G, Meissner R, Mello VBB, Melo D, Menshikov A, Messina S, Micheletti MI, Middendorf L, Minaya IA, Miramonti L, Mitrica B, Molina-Bueno L, Mollerach S, Montanet F, Morello C, Mostafá M, Moura CA, Muller MA, Müller G, Müller S, Navas S, Necesal P, Nellen L, Nelles A, Neuser J, Nguyen PH, Niculescu-Oglinzanu M, Niechciol M, Niemietz L, Niggemann T, Nitz D, Nosek D, Novotny V, Nožka L, Núñez LA, Ochilo L, Oikonomou F, Olinto A, Pacheco N, Pakk Selmi-Dei D, Palatka M, Pallotta J, Papenbreer P, Parente G, Parra A, Paul T, Pech M, Pȩkala J, Pelayo R, Pepe IM, Perrone L, Petermann E, Peters C, Petrera S, Petrov Y, Phuntsok J, Piegaia R, Pierog T, Pieroni P, Pimenta M, Pirronello V, Platino M, Plum M, Porcelli A, Porowski C, Prado RR, Privitera P, Prouza M, Quel EJ, Querchfeld S, Quinn S, Rautenberg J, Ravel O, Ravignani D, Reinert D, Revenu B, Ridky J, Risse M, Ristori P, Rizi V, Rodrigues de Carvalho W, Rodriguez Rojo J, Rodríguez-Frías MD, Rogozin D, Rosado J, Roth M, Roulet E, Rovero AC, Saffi SJ, Saftoiu A, Salazar H, Saleh A, Salesa Greus F, Salina G, Sanabria Gomez JD, Sánchez F, Sanchez-Lucas P, Santos E, Santos EM, Sarazin F, Sarkar B, Sarmento R, Sarmiento-Cano C, Sato R, Scarso C, Schauer M, Scherini V, Schieler H, Schmidt D, Scholten O, Schoorlemmer H, Schovánek P, Schröder FG, Schulz A, Schulz J, Schumacher J, Sciutto SJ, Segreto A, Settimo M, Shadkam A, Shellard RC, Sigl G, Sima O, Śmiałkowski A, Šmída R, Snow GR, Sommers P, Sonntag S, Sorokin J, Squartini R, Srivastava YN, Stanca D, Stanič S, Stapleton J, Stasielak J, Stephan M, Stutz A, Suarez F, Suarez Durán M, Suomijärvi T, Supanitsky AD, Sutherland MS, Swain J, Szadkowski Z, Taborda OA, Tapia A, Tepe A, Theodoro VM, Timmermans C, Todero Peixoto CJ, Toma G, Tomankova L, Tomé B, Tonachini A, Torralba Elipe G, Torres Machado D, Travnicek P, Trini M, Ulrich R, Unger M, Urban M, Valdés Galicia JF, Valiño I, Valore L, van Aar G, van Bodegom P, van den Berg AM, van Velzen S, van Vliet A, Varela E, Vargas Cárdenas B, Varner G, Vasquez R, Vázquez JR, Vázquez RA, Veberič D, Verzi V, Vicha J, Videla M, Villaseñor L, Vlcek B, Vorobiov S, Wahlberg H, Wainberg O, Walz D, Watson AA, Weber M, Weidenhaupt K, Weindl A, Welling C, Werner F, Widom A, Wiencke L, Wilczyński H, Winchen T, Wittkowski D, Wundheiler B, Wykes S, Yang L, Yapici T, Yushkov A, Zas E, Zavrtanik D, Zavrtanik M, Zepeda A, Zimmermann B, Ziolkowski M, Zuccarello F. Measurement of the Radiation Energy in the Radio Signal of Extensive Air Showers as a Universal Estimator of Cosmic-Ray Energy. PHYSICAL REVIEW LETTERS 2016; 116:241101. [PMID: 27367377 DOI: 10.1103/physrevlett.116.241101] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/27/2015] [Indexed: 06/06/2023]
Abstract
We measure the energy emitted by extensive air showers in the form of radio emission in the frequency range from 30 to 80 MHz. Exploiting the accurate energy scale of the Pierre Auger Observatory, we obtain a radiation energy of 15.8±0.7(stat)±6.7(syst) MeV for cosmic rays with an energy of 1 EeV arriving perpendicularly to a geomagnetic field of 0.24 G, scaling quadratically with the cosmic-ray energy. A comparison with predictions from state-of-the-art first-principles calculations shows agreement with our measurement. The radiation energy provides direct access to the calorimetric energy in the electromagnetic cascade of extensive air showers. Comparison with our result thus allows the direct calibration of any cosmic-ray radio detector against the well-established energy scale of the Pierre Auger Observatory.
Collapse
|
37
|
Leuci V, Maione F, Rotolo R, Giraudo E, Sassi F, Migliardi G, Todorovic M, Gammaitoni L, Mesiano G, Giraudo L, Luraghi P, Leone F, Bussolino F, Grignani G, Aglietta M, Trusolino L, Bertotti A, Sangiolo D. Lenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activity. J Transl Med 2016; 14:119. [PMID: 27149858 PMCID: PMC4857418 DOI: 10.1186/s12967-016-0872-2] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2015] [Accepted: 04/20/2016] [Indexed: 12/19/2022] Open
Abstract
Background Angiogenesis inhibition is a promising approach for treating metastatic colorectal cancer (mCRC). Recent evidences support the seemingly counterintuitive ability of certain antiangiogenic drugs to promote normalization of residual tumor vessels with important clinical implications. Lenalidomide is an oral drug with immune-modulatory and anti-angiogenic activity against selected hematologic malignancies but as yet little is known regarding its effectiveness for solid tumors. The aim of this study was to determine whether lenalidomide can normalize colorectal cancer neo-vessels in vivo, thus reducing tumor hypoxia and improving the benefit of chemotherapy. Methods We set up a tumorgraft model with NOD/SCID mice implanted with a patient-derived colorectal cancer liver metastasis. The mice were treated with oral lenalidomide (50 mg/Kg/day for 28 days), intraperitoneal 5-fluorouracil (5FU) (20 mg/Kg twice weekly for 3 weeks), combination (combo) of lenalidomide and 5FU or irrelevant vehicle. We assessed tumor vessel density (CD146), pericyte coverage (NG2; alphaSMA), in vivo perfusion capability of residual vessels (lectin distribution essay), hypoxic areas (HP2-100 Hypoxyprobe) and antitumor activity in vivo and in vitro. Results Treatment with lenalidomide reduced tumor vessel density (p = 0.0001) and enhanced mature pericyte coverage of residual vessels (p = 0.002). Perfusion capability of tumor vessels was enhanced in mice treated with lenalidomide compared to controls (p = 0.004). Accordingly, lenalidomide reduced hypoxic tumor areas (p = 0.002) and enhanced the antitumor activity of 5FU in vivo. The combo treatment delayed tumor growth (p = 0.01) and significantly reduced the Ki67 index (p = 0.0002). Lenalidomide alone did not demonstrate antitumor activity compared to untreated controls in vivo or against 4 different mCRC cell lines in vitro. Conclusions We provide the first evidence of tumor vessel normalization and hypoxia reduction induced by lenalidomide in mCRC in vivo. This effect, seemingly counterintuitive for an antiangiogenic compound, translates into indirect antitumor activity thus enhancing the therapeutic index of chemotherapy. Our findings suggest that further research should be carried out on synergism between lenalidomide and conventional therapies for treating solid tumors that might benefit from tumor vasculature normalization.
Collapse
|
38
|
Marocco F, Vaira M, Milani A, Genta S, Maggiorotto F, Magistris A, Cinquegrana A, Robella M, De Simone M, Aglietta M, Ponzone R, Valabrega G. Secondary cytoreductive surgery, hyperthermic intraperitoneal intraoperative chemotherapy, and chemotherapy alone: a retrospective comparison of alternative approaches in relapsed platinum sensitive ovarian cancer. EUR J GYNAECOL ONCOL 2016; 37:638-643. [PMID: 29787001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
INTRODUCTION The best treatment for relapsed platinum sensitive epithelial ovarian cancer (EOC) is controversial. The aim of the study was to compare progression-free survival (PFS) and overall survival (OS) in platinum-sensitive EOC patients treated with chemotherapy alone (CTA), secondary cytoreductive surgery (SCR) or SCR plus hyperthermic intraperitoneal intraoperative chemotherapy (HIPEC). MATERIALS AND METHODS Retrospective analysis of the clinical outcome of 46 EOC patients with at least 30 months of follow-up. RESULTS Median follow-up time was 32 months for the CTA group, 30 months for the SCR group, and 45 months for the SCR + HIPEC group. Fifteen recurrences were observed in the CTA group, seven in the SCR group, and 16 in the SCR + HIPEC group. The median time elapsed between first and second recurrence (PFI-2) was significantly higher among patients treated with SCR + HIPEC, in comparison with patients treated with CTA (p = 0.012 andp = 0.017, respectively). On the contrary, PFI-2 did not significantly differ between the SCR and SCR + HIPEC groups (p = 0.877). A statistically significant difference in OS favouring SCR + HIPEC in comparison with CTA (p = 0.04) was observed. CONCLUSIONS SCR HIPEC compared with CTA improves PFI-2 in patients with platinum-sensitive EOC recurrence. SCR + HIPEC might also improve OS in comparison with CTA. No improvement in favor of SCR + HIPEC vs SCR was observed,. These results further support the need of a randomized trial comparing chemotherapy with SCR ± HIPEC in this setting.
Collapse
|
39
|
Tampellini M, Polverari RS, Ottone A, Alabiso I, Baratelli C, Bitossi R, Brizzi MP, Leone F, Forti L, Bertona E, Racca P, Mecca C, Alabiso O, Aglietta M, Berruti A, Scagliotti GV. Circannual variation of efficacy outcomes in patients with newly diagnosed metastatic colorectal cancer and treated with first-line chemotherapy. Chronobiol Int 2015; 32:1359-66. [PMID: 26540634 DOI: 10.3109/07420528.2015.1093495] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Seasonal variation of baseline diagnosis (or clinical suspect) of stage I-III colorectal cancer patients has been repeatedly reported as an independent variable influencing overall survival. However, data are conflicting and no information is available about such a rhythm in advanced stage patients. To test whether a circannual rhythm of efficacy outcomes can be detected in this setting, we collected data about response rate (RR), progression-free survival (PFS), and overall survival (OS) to first-line chemotherapy of 1610 newly diagnosed metastatic patients treated at four independent centers. Responses to first-line chemotherapy were available for 1495 patients. A strong circannual rhythm in RR was evident, with the higher proportion of responding patients in the subgroup diagnosed in January (acrophase). At the time of data cutoff, 1322 patients progressed and 986 died, with median PFS and OS of 11 and 25.6 months, respectively. A circannual rhythmicity of the proportion of patients progressing at 6 months and surviving at 1 year was demonstrated, with acrophases located both in winter (February and January, respectively), similar to what reported for RR. Several interpretations about the genesis of this cyclic variation could be claimed: the rhythm in sunlight exposure and, as a consequence, of vitamin D serum levels and folate degradation, the variability in toxic effect intensity of chemotherapy, and the rhythm in the biological behavior of tumor cells. This observation is worth of further investigation both in preclinical and in clinical settings in order to better elucidate the underlying mechanisms.
Collapse
|
40
|
Rosati G, Nasti G, Lonardi S, Zaniboni A, Romiti A, Aglietta M, Bilancia D, Iaffaioli V, Marsico V, Giordano M, Corsi D, Ferraù F, Labianca R, Berardi R, Galli F, Frontini L, Cascinu S. A phase III multicenter trial comparing two different sequences of second/third line therapy (irinotecan/cetuximab followed by FOLFOX-4 vs. FOLFOX-4 followed by irinotecan/cetuximab in K-RAS wt metastatic colorectal cancer (mCC) patients refractory to FOLFIRI/Bevacizumab. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv335.03] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
41
|
Laface R, Venesio T, Cagnazzo C, Pollato K, Cicako T, Aglietta M, Garetto L. Rare epidermal growth factor receptor (EGFR) mutations in a 425 patients population with non-small cell lung cancer (NSCLC): clinical, molecular and survival data. The IRCCS Candiolo experience. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv343.15] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
42
|
Marino D, Filippi R, Cereda S, Belli C, Spadi R, Nasti G, Montano M, Amatu A, Lutrino S, Cagnazzo C, Ferrari L, Siena S, Ciuffreda L, Reni M, Aglietta M, Leone F. Multicenter randomized study of Gemcitabine and Oxaliplatin (GEMOX) +/- Panitumumab as First Line Treatment in K-Ras Wild type Advanced Biliary Tract Cancer; the VECTI-BIL study. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv344.02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
43
|
Paganelli G, Rossetti C, Aglietta M, Messina C, Versari A, Michalski J, O'Sullivan J, Parker C, Garcia-Vargas J, Sartor A, Finkelstein S. External beam radiation therapy (EBRT) use and safety with radium-223 dichloride (Ra-223) in patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets) from the ALSYMPCA trial. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv341.31] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
44
|
Amadori D, Rossetti C, Aglietta M, Messina C, Versari A, Vogelzang N, Sartor A, Coleman R, Govi S, Fang F, Skjorestad I, Nilsson S, Parker C. 3-year safety follow-up of radium-223 dichloride (Ra-223) in patients (Pts) with castration resistant prostate cancer (CRPC) and symptomatic bone metastases (Mets) from ALSYMPCA. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv341.07] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
45
|
Tampellini M, Ottone A, Alabiso I, Baratelli C, Bitossi R, Brizzi M, Leone F, Forti L, Bertona E, Racca P, Mecca C, Alabiso O, Aglietta M, Berruti A, Scagliotti G. Circannual variation of efficacy outcomes in patients with newly diagnosed metastatic colorectal cancer and treated with first-line chemotherapy. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv340.28] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
46
|
Cascinu S, Lonardi S, Rosati G, Nasti G, Zaniboni A, Romiti A, Aglietta M, Bilancia D, Iaffaioli V, Zagonel V, Giordano M, Corsi D, Ferraù F, Labianca R, Berardi R, Rulli E, Floriani I. 2006 A phase III multicenter trial comparing two different sequences of second/third line therapy (cetuximab/irinotecan followed by FOLFOX versus FOLFOX followed by cetuximab/irinotecan) in metastatic K-RAS wt colorectal cancer (mCC) patients, refractory to FOLFIRI/Bevacizumab). Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(15)30040-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
47
|
Aab A, Abreu P, Aglietta M, Ahn EJ, Samarai IA, Albuquerque IFM, Allekotte I, Allen J, Allison P, Almela A, Castillo JA, Alvarez-Muñiz J, Batista RA, Ambrosio M, Aminaei A, Anchordoqui L, Andringa S, Aramo C, Aranda VM, Arqueros F, Asorey H, Assis P, Aublin J, Ave M, Avenier M, Avila G, Awal N, Badescu AM, Barber KB, Bäuml J, Baus C, Beatty JJ, Becker KH, Bellido JA, Berat C, Bertaina ME, Bertou X, Biermann PL, Billoir P, Blaess S, Blanco M, Bleve C, Blümer H, Boháčová M, Boncioli D, Bonifazi C, Bonino R, Borodai N, Brack J, Brancus I, Bridgeman A, Brogueira P, Brown WC, Buchholz P, Bueno A, Buitink S, Buscemi M, Caballero-Mora KS, Caccianiga B, Caccianiga L, Candusso M, Caramete L, Caruso R, Castellina A, Cataldi G, Cazon L, Cester R, Chavez AG, Chiavassa A, Chinellato JA, Chudoba J, Cilmo M, Clay RW, Cocciolo G, Colalillo R, Coleman A, Collica L, Coluccia MR, Conceição R, Contreras F, Cooper MJ, Cordier A, Coutu S, Covault CE, Cronin J, Curutiu A, Dallier R, Daniel B, Dasso S, Daumiller K, Dawson BR, Almeida RMD, Domenico MD, Jong SJD, Neto JRTDM, Mitri ID, Oliveira JD, Souza VD, Peral LD, Deligny O, Dembinski H, Dhital N, Giulio CD, Matteo AD, Diaz JC, Castro MLD, Diogo F, Dobrigkeit C, Docters W, D’Olivo JC, Dorofeev A, Hasankiadeh QD, Dova MT, Ebr J, Engel R, Erdmann M, Erfani M, Escobar CO, Espadanal J, Etchegoyen A, Luis PFS, Falcke H, Fang K, Farrar G, Fauth AC, Fazzini N, Ferguson AP, Fernandes M, Fick B, Figueira JM, Filevich A, Filipčič A, Fox BD, Fratu O, Fröhlich U, Fuchs B, Fujii T, Gaior R, García B, Roca STG, Garcia-Gamez D, Garcia-Pinto D, Garilli G, Bravo AG, Gate F, Gemmeke H, Ghia PL, Giaccari U, Giammarchi M, Giller M, Glaser C, Glass H, Berisso MG, Vitale PFG, Gonçalves P, Gonzalez JG, González N, Gookin B, Gordon J, Gorgi A, Gorham P, Gouffon P, Grebe S, Griffith N, Grillo AF, Grubb TD, Guarino F, Guedes GP, Hampel MR, Hansen P, Harari D, Harrison TA, Hartmann S, Harton JL, Haungs A, Hebbeker T, Heck D, Heimann P, Herve AE, Hill GC, Hojvat C, Hollon N, Holt E, Homola P, Hörandel JR, Horvath P, Hrabovský M, Huber D, Huege T, Insolia A, Isar PG, Jandt I, Jansen S, Jarne C, Josebachuili M, Kääpä A, Kambeitz O, Kampert KH, Kasper P, Katkov I, Kégl B, Keilhauer B, Keivani A, Kemp E, Kieckhafer RM, Klages HO, Kleifges M, Kleinfeller J, Krause R, Krohm N, Krömer O, Kruppke-Hansen D, Kuempel D, Kunka N, LaHurd D, Latronico L, Lauer R, Lauscher M, Lautridou P, Coz SL, Leão MSAB, Lebrun D, Lebrun P, Oliveira MALD, Letessier-Selvon A, Lhenry-Yvon I, Link K, López R, Agüera AL, Louedec K, Bahilo JL, Lu L, Lucero A, Ludwig M, Malacari M, Maldera S, Mallamaci M, Maller J, Mandat D, Mantsch P, Mariazzi AG, Marin V, Mariş IC, Marsella G, Martello D, Martin L, Martinez H, Bravo OM, Martraire D, Meza JJM, Mathes HJ, Mathys S, Matthews J, Matthews JAJ, Matthiae G, Maurel D, Maurizio D, Mayotte E, Mazur PO, Medina C, Medina-Tanco G, Meissner R, Melissas M, Melo D, Menshikov A, Messina S, Meyhandan R, Mićanović S, Micheletti MI, Middendorf L, Minaya IA, Miramonti L, Mitrica B, Molina-Bueno L, Mollerach S, Monasor M, Ragaigne DM, Montanet F, Morello C, Mostafá M, Moura CA, Muller MA, Müller G, Müller S, Münchmeyer M, Mussa R, Navarra G, Navas S, Necesal P, Nellen L, Nelles A, Neuser J, Nguyen P, Niechciol M, Niemietz L, Niggemann T, Nitz D, Nosek D, Novotny V, Nožka L, Ochilo L, Olinto A, Oliveira M, Pacheco N, Selmi-Dei DP, Palatka M, Pallotta J, Palmieri N, Papenbreer P, Parente G, Parra A, Paul T, Pech M, Pȩkala J, Pelayo R, Pepe IM, Perrone L, Petermann E, Peters C, Petrera S, Petrov Y, Phuntsok J, Piegaia R, Pierog T, Pieroni P, Pimenta M, Pirronello V, Platino M, Plum M, Porcelli A, Porowski C, Prado RR, Privitera P, Prouza M, Purrello V, Quel EJ, Querchfeld S, Quinn S, Rautenberg J, Ravel O, Ravignani D, Revenu B, Ridky J, Riggi S, Risse M, Ristori P, Rizi V, Carvalho WRD, Cabo IR, Fernandez GR, Rojo JR, Rodríguez-Frías MD, Rogozin D, Ros G, Rosado J, Rossler T, Roth M, Roulet E, Rovero AC, Saffi SJ, Saftoiu A, Salamida F, Salazar H, Saleh A, Greus FS, Salina G, Sánchez F, Sanchez-Lucas P, Santo CE, Santos E, Santos EM, Sarazin F, Sarkar B, Sarmento R, Sato R, Scharf N, Scherini V, Schieler H, Schiffer P, Schmidt D, Schröder FG, Scholten O, Schoorlemmer H, Schovánek P, Schulz A, Schulz J, Schumacher J, Sciutto SJ, Segreto A, Settimo M, Shadkam A, Shellard RC, Sidelnik I, Sigl G, Sima O, kowski AŚ, Šmída R, Snow GR, Sommers P, Sorokin J, Squartini R, Srivastava YN, Stanič S, Stapleton J, Stasielak J, Stephan M, Stutz A, Suarez F, Suomijärvi T, Supanitsky AD, Sutherland MS, Swain J, Szadkowski Z, Szuba M, Taborda OA, Tapia A, Tartare M, Tepe A, Theodoro VM, Timmermans C, Peixoto CJT, Toma G, Tomankova L, Tomé B, Tonachini A, Elipe GT, Machado DT, Travnicek P, Trovato E, Tueros M, Ulrich R, Unger M, Urban M, Galicia JFV, Valiño I, Valore L, Aar GV, Bodegom PV, Berg AMVD, Velzen SV, Vliet AV, Varela E, Vargas Cárdenas B, Varner G, Vázquez JR, Vázquez RA, Veberič D, Verzi V, Vicha J, Videla M, Villaseñor L, Vlcek B, Vorobiov S, Wahlberg H, Wainberg O, Walz D, Watson AA, Weber M, Weidenhaupt K, Weindl A, Werner F, Widom A, Wiencke L, Wilczyńska B, Wilczyński H, Will M, Williams C, Winchen T, Wittkowski D, Wundheiler B, Wykes S, Yamamoto T, Yapici T, Yuan G, Yushkov A, Zamorano B, Zas E, Zavrtanik D, Zavrtanik M, Zaw I, Zepeda A, Zhou J, Zhu Y, Silva MZ, Ziolkowski M, Zuccarello F. Search for patterns by combining cosmic-ray energy and arrival directions at the Pierre Auger Observatory. THE EUROPEAN PHYSICAL JOURNAL. C, PARTICLES AND FIELDS 2015; 75:269. [PMID: 26120280 PMCID: PMC4477714 DOI: 10.1140/epjc/s10052-015-3471-0] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 10/03/2014] [Accepted: 05/20/2015] [Indexed: 06/04/2023]
Abstract
Energy-dependent patterns in the arrival directions of cosmic rays are searched for using data of the Pierre Auger Observatory. We investigate local regions around the highest-energy cosmic rays with [Formula: see text] eV by analyzing cosmic rays with energies above [Formula: see text] eV arriving within an angular separation of approximately 15[Formula: see text]. We characterize the energy distributions inside these regions by two independent methods, one searching for angular dependence of energy-energy correlations and one searching for collimation of energy along the local system of principal axes of the energy distribution. No significant patterns are found with this analysis. The comparison of these measurements with astrophysical scenarios can therefore be used to obtain constraints on related model parameters such as strength of cosmic-ray deflection and density of point sources.
Collapse
|
48
|
Marino D, Filippi R, Cereda S, Belli C, Spadi R, Nasti G, Montano M, Amatu A, Lutrino S, Cagnazzo C, Ferrari L, Siena S, Ciuffreda L, Reni M, Aglietta M, Leone F. PD-006 Gemcitabine and Oxaliplatin (GEMOX) with or without Panitumumab as First-Line Treatment in Advanced Biliary Tract Cancer; final results and subgroup analysis of the Vecti-BIL Study. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv234.05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
49
|
Aab A, Abreu P, Aglietta M, Ahn E, Al Samarai I, Albuquerque I, Allekotte I, Allen J, Allison P, Almela A, Alvarez Castillo J, Alvarez-Muñiz J, Alves Batista R, Ambrosio M, Aminaei A, Anchordoqui L, Andringa S, Aramo C, Aranda V, Arqueros F, Asorey H, Assis P, Aublin J, Ave M, Avenier M, Avila G, Badescu A, Barber K, Bäuml J, Baus C, Beatty J, Becker K, Bellido J, Berat C, Bertaina M, Bertou X, Biermann P, Billoir P, Blanco M, Bleve C, Blümer H, Boháčová M, Boncioli D, Bonifazi C, Bonino R, Borodai N, Brack J, Brancus I, Brogueira P, Brown W, Buchholz P, Bueno A, Buitink S, Buscemi M, Caballero-Mora K, Caccianiga B, Caccianiga L, Candusso M, Caramete L, Caruso R, Castellina A, Cataldi G, Cazon L, Cester R, Chavez A, Chiavassa A, Chinellato J, Chudoba J, Cilmo M, Clay R, Cocciolo G, Colalillo R, Coleman A, Collica L, Coluccia M, Conceição R, Contreras F, Cooper M, Cordier A, Coutu S, Covault C, Cronin J, Curutiu A, Dallier R, Daniel B, Dasso S, Daumiller K, Dawson B, de Almeida R, De Domenico M, de Jong S, de Mello Neto J, De Mitri I, de Oliveira J, de Souza V, del Peral L, Deligny O, Dembinski H, Dhital N, Di Giulio C, Di Matteo A, Diaz J, Díaz Castro M, Diogo F, Dobrigkeit C, Docters W, D’Olivo J, Dorofeev A, Dorosti Hasankiadeh Q, Dova M, Ebr J, Engel R, Erdmann M, Erfani M, Escobar C, Espadanal J, Etchegoyen A, Facal San Luis P, Falcke H, Fang K, Farrar G, Fauth A, Fazzini N, Ferguson A, Fernandes M, Fick B, Figueira J, Filevich A, Filipčič A, Fox B, Fratu O, Fröhlich U, Fuchs B, Fujii T, Gaior R, García B, Garcia Roca S, Garcia-Gamez D, Garcia-Pinto D, Garilli G, Gascon Bravo A, Gate F, Gemmeke H, Ghia P, Giaccari U, Giammarchi M, Giller M, Glaser C, Glass H, Gómez Berisso M, Gómez Vitale P, Gonçalves P, Gonzalez J, González N, Gookin B, Gordon J, Gorgi A, Gorham P, Gouffon P, Grebe S, Griffith N, Grillo A, Grubb T, Guardincerri Y, Guarino F, Guedes G, Hampel M, Hansen P, Harari D, Harrison T, Hartmann S, Harton J, Haungs A, Hebbeker T, Heck D, Heimann P, Herve A, Hill G, Hojvat C, Hollon N, Holt E, Homola P, Hörandel J, Horvath P, Hrabovský M, Huber D, Huege T, Insolia A, Isar P, Islo K, Jandt I, Jansen S, Jarne C, Josebachuili M, Kääpä A, Kambeitz O, Kampert K, Kasper P, Katkov I, Kégl B, Keilhauer B, Keivani A, Kemp E, Kieckhafer R, Klages H, Kleifges M, Kleinfeller J, Krause R, Krohm N, Krömer O, Kruppke-Hansen D, Kuempel D, Kunka N, LaHurd D, Latronico L, Lauer R, Lauscher M, Lautridou P, Le Coz S, Leão M, Lebrun D, Lebrun P, Leigui de Oliveira M, Letessier-Selvon A, Lhenry-Yvon I, Link K, López R, Louedec K, Lozano Bahilo J, Lu L, Lucero A, Ludwig M, Malacari M, Maldera S, Mallamaci M, Maller J, Mandat D, Mantsch P, Mariazzi A, Marin V, Mariş I, Marsella G, Martello D, Martin L, Martinez H, Martínez Bravo O, Martraire D, Masías Meza J, Mathes H, Mathys S, Matthews J, Matthews J, Matthiae G, Maurel D, Maurizio D, Mayotte E, Mazur P, Medina C, Medina-Tanco G, Melissas M, Melo D, Menshikov A, Messina S, Meyhandan R, Mićanović S, Micheletti M, Middendorf L, Minaya I, Miramonti L, Mitrica B, Molina-Bueno L, Mollerach S, Monasor M, Monnier Ragaigne D, Montanet F, Morello C, Mostafá M, Moura C, Muller M, Müller G, Münchmeyer M, Mussa R, Navarra G, Navas S, Necesal P, Nellen L, Nelles A, Neuser J, Newton D, Niechciol M, Niemietz L, Niggemann T, Nitz D, Nosek D, Novotny V, Nožka L, Ochilo L, Olinto A, Oliveira M, Olmos-Gilbaja V, Pacheco N, Pakk Selmi-Dei D, Palatka M, Pallotta J, Palmieri N, Papenbreer P, Parente G, Parra A, Paul T, Pech M, Pękala J, Pelayo R, Pepe I, Perrone L, Petermann E, Peters C, Petrera S, Petrov Y, Phuntsok J, Piegaia R, Pierog T, Pieroni P, Pimenta M, Pirronello V, Platino M, Plum M, Porcelli A, Porowski C, Prado R, Privitera P, Prouza M, Purrello V, Quel E, Querchfeld S, Quinn S, Rautenberg J, Ravel O, Ravignani D, Revenu B, Ridky J, Riggi S, Risse M, Ristori P, Rizi V, Roberts J, Rodrigues de Carvalho W, Rodriguez Fernandez G, Rodriguez Rojo J, Rodríguez-Frías M, Ros G, Rosado J, Rossler T, Roth M, Roulet E, Rovero A, Saffi S, Saftoiu A, Salamida F, Salazar H, Saleh A, Salesa Greus F, Salina G, Sánchez F, Sanchez-Lucas P, Santo C, Santos E, Santos E, Sarazin F, Sarkar B, Sarmento R, Sato R, Scharf N, Scherini V, Schieler H, Schiffer P, Scholten O, Schoorlemmer H, Schovánek P, Schröder F, Schulz A, Schulz J, Schumacher J, Sciutto S, Segreto A, Settimo M, Shadkam A, Shellard R, Sidelnik I, Sigl G, Sima O, Śmiałkowski A, Šmída R, Snow G, Sommers P, Sorokin J, Squartini R, Srivastava Y, Stanič S, Stapleton J, Stasielak J, Stephan M, Stutz A, Suarez F, Suomijärvi T, Supanitsky A, Sutherland M, Swain J, Szadkowski Z, Szuba M, Taborda O, Tapia A, Tartare M, Tepe A, Theodoro V, Timmermans C, Todero Peixoto C, Toma G, Tomankova L, Tomé B, Tonachini A, Torralba Elipe G, Torres Machado D, Travnicek P, Trovato E, Ulrich R, Unger M, Urban M, Valdés Galicia J, Valiño I, Valore L, van Aar G, van den Berg A, van Velzen S, van Vliet A, Varela E, Vargas Cárdenas B, Varner G, Vázquez J, Vázquez R, Veberič D, Verzi V, Vicha J, Videla M, Villaseñor L, Vlcek B, Vorobiov S, Wahlberg H, Wainberg O, Walz D, Watson A, Weber M, Weidenhaupt K, Weindl A, Werner F, Widom A, Wiencke L, Wilczyńska B, Wilczyński H, Will M, Williams C, Winchen T, Wittkowski D, Wundheiler B, Wykes S, Yamamoto T, Yapici T, Younk P, Yuan G, Yushkov A, Zamorano B, Zas E, Zavrtanik D, Zavrtanik M, Zaw I, Zepeda A, Zhou J, Zhu Y, Zimbres Silva M, Ziolkowski M, Zuccarello F. Muons in air showers at the Pierre Auger Observatory: Mean number in highly inclined events. Int J Clin Exp Med 2015. [DOI: 10.1103/physrevd.91.032003] [Citation(s) in RCA: 119] [Impact Index Per Article: 13.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
50
|
Aglietta M, Barone C, Sawyer MB, Moore MJ, Miller WH, Bagalà C, Colombi F, Cagnazzo C, Gioeni L, Wang E, Huang B, Fly KD, Leone F. A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer. Ann Oncol 2014; 25:1750-1755. [PMID: 24907635 DOI: 10.1093/annonc/mdu205] [Citation(s) in RCA: 144] [Impact Index Per Article: 14.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
BACKGROUND Tremelimumab (CP-675,206) is a fully human monoclonal antibody binding to cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) on T cells that stimulates the immune system by blocking the CTLA4-negative regulatory signal. Combination with standard chemotherapy may strengthen antitumor therapy. This is a phase Ib, multisite, open-label, nonrandomized dose escalation trial evaluating the safety, tolerability, and maximum tolerated dose (MTD) of tremelimumab combined with gemcitabine in patients with metastatic pancreatic cancer. PATIENTS AND METHODS Gemcitabine (1000 mg/m(2) on days 1, 8, and 15 of each 28-day cycles) was administrated with escalating doses of i.v. tremelimumab (6, 10, or 15 mg/kg) on day 1 of each 84-day cycle for a maximum of 4 cycles. The first 18 patients had an initial 4-week gemcitabine-only lead-in period. Dose-limiting toxicities (DLTs) related to tremelimumab were evaluated during the first 6 weeks after the first dose of tremelimumab. RESULTS From June 2008 to August 2011, 34 patients were enrolled and received at least one dose of tremelimumab. No DLTs related to tremelimumab were observed at any dose, even when the maximum dose established for tremelimumab (15 mg/kg) was used. Most frequent grade 3/4 toxicities were asthenia (11.8%) and nausea (8.8%). Only one patient had a serious drug-related event (diarrhea with dehydration). The median overall survival was 7.4 months (95% confidence interval 5.8-9.4 months). At the end of treatment, two patients achieved partial response. Both patients received tremelimumab 15-mg/kg group (n = 2/19, 10.5%). CONCLUSION Tremelimumab plus gemcitabine demonstrated a safety and tolerability profile, warranting further study in patients with metastatic pancreatic cancer. CLINICALTRIALSGOV ID NCT00556023.
Collapse
|